Showing Results for: “diabetes”

The first sub-analysis of renal data from the Dapagliflozin Effect on Cardiovascular Events Thrombolysis In Myocardial Infarction (DECLARE-TIMI 58) trial indicates that dapagliflozin, an oral sodium glucose cotransporter 2 (SGLT2) inhibitor, reduced the progression of kidney disease or renal death in patients with type 2 diabetes (T2D). The initial results from the trial, the first cardiovascular outcome study to enroll a large cohort of patients with diabetes risk factors for Atherosclerotic Cardiovascular Disease (ASCVD) and a large number of patients with diabetes with known ASCVD, were

The American Diabetes Association (ADA) welcomes the 2020 Principal Officers and Board of Directors. The 18-member board is comprised of forward-thinking, innovative medical, scientific, education and executive professionals, who will strategically lead and focus efforts to ensure the ADA continues to be synonymous with excellence. "We are thrilled to welcome the newest members of ADA’s National Board of Directors,” said Tracey D. Brown, Chief Executive Officer of the ADA. “With the help of these talented and dedicated experts, we will continue the important work that leads us closer and

ADA Leads 20 National Patient Advocate Groups Urging USPS Delivery Improvements The American Diabetes Association® (ADA), along with 19 other national health groups, today called on the U.S. Postal Service Postmaster General Louis DeJoy to reinstate the organization’s delivery standards as well as expressed concerns over the effect the current delays could have on 133 million Americans who suffer from chronic disease and may rely on medication deliveries to receive life-saving drugs. “While we appreciate that you have committed to halt the changes implemented earlier this summer, we believe

Hybrid closed-loop technology effectively helped women stay in target glucose range for longer compared to standard of care A new study shows pregnant women with type 1 diabetes stayed in the target blood glucose (blood sugar) range for pregnancy more often with an automated insulin delivery (AID) system (Control-IQ Technology) that is currently available for use—but not approved in pregnancy—compared to standard insulin delivery with injections or open-loop insulin pump therapy (non-automated) with continuous glucose monitoring (CGM). The results will be presented as a late-breaking poster at

The American Diabetes Association (ADA) welcomes the 2021 Principal Officers and Board of Directors. The 17-member board is comprised of forward-thinking, innovative medical, scientific, education and executive business professionals, who will strategically lead and focus efforts to ensure the ADA continues to uphold the mission upon which it was founded. "I am so excited to announce our 2021 Board of Directors, including five new Board members,” said Tracey D. Brown, Chief Executive Officer of the ADA. “I look forward to the insight and skills that each of these thought leaders will provide

Awards given to hospitals nationwide for leadership in caring for the 30% of inpatient Americans who are living with diabetes Today, the American Diabetes Association® (ADA) and The Leapfrog Group named 36 hospitals across 12 states as 2025 Recognized Leaders in Caring for People Living with Diabetes. The award recognizes each hospital’s strong commitment to the safety and well-being of hospitalized people living with diabetes—estimated to be 30% of all people who are inpatient nationwide. Now in its second year, the number of award recipients has more than doubled, reflecting a growing

Consensus report outlines the positive impact of diabetes self-management education and support and the critical need for increased access Seven leading diabetes organizations issued a consensus report today highlighting the value of diabetes self-management education and support (DSMES) services as part of comprehensive diabetes medical care. The report provides compelling evidence for the need for increased utilization of DSMES, four key times that DSMES is most beneficial, and specific recommendations for both clinicians and health systems to increase access to and participation in DSMES

The ADA’s Education Recognition Program certification ensures quality diabetes education and support for people living with diabetes. Today, the American Diabetes Association® (ADA)—a leading organization committed to fighting to end diabetes—announced the recognition of DiaServ’s diabetes self-management education and support (DSMES) service by the ADA’s Education Recognition Program (ERP). The ADA’s ERP certificate assures that educational services meet the National Standards for DSMES. The corresponding intervention provided is evidence-based and outcome-driven. Services apply for

Research Presented at the ADA’s Scientific Sessions Highlights Need to Address Health Equity to Improve Diabetes Management and Outcomes Today, two studies provide evidence that social determinants of health account for disparities in health outcomes related to diabetes. Both studies were released as poster presentations at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA) in New Orleans, LA. This research comes at a time when individuals with lower socioeconomic status are more likely to develop diabetes, experience more complications, and die sooner than those with a

On June 20, the American Diabetes Association ® (ADA) will host its signature fundraising event to raise awareness, connect communities, and strengthen critical support for individuals and families impacted by diabetes. Step Out ® Walk: Greater New York will bring together the diabetes community, volunteers, and advocates for a meaningful walk welcoming people of all ages and abilities. Time and date: Saturday, June 20 at 8:30 a.m. Location: Adelphi University, 1 South Ave., Garden City, NY 11530 Register, start or join a team, and fundraise: stepout.diabetes.org/StepOutNewYork Step Out Walk